TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates

Core Viewpoint - TScan Therapeutics, Inc. reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of$0.28, indicating a positive earnings surprise of 10.71% [1] Financial Performance - The company posted revenues of $1.05 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 63.36$3.89 million in the same quarter last year [2] - Over the last four quarters, TScan Therapeutics has surpassed consensus EPS estimates three times [2] Stock Performance - TScan Therapeutics shares have decreased by approximately 2.2% since the beginning of the year, contrasting with the S&P 500's gain of 25.8% [3] Future Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.28 on revenues of$6.19 million, and for the current fiscal year, it is -$1.17 on revenues of$10.15 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which TScan Therapeutics belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable industry outlook [8]